New formulations and methods of use of tiropride
By introducing an alkaline agent and enteric coating into telolide formulations, the gastric side effects and pharmacokinetic issues of existing formulations have been resolved, resulting in faster drug absorption and higher bioavailability, and improved patient compliance.
CN122374013APending Publication Date: 2026-07-10BIOPROJET PHARMA
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BIOPROJET PHARMA
- Filing Date
- 2024-10-15
- Publication Date
- 2026-07-10
AI Technical Summary
Technical Problem
Existing telolide formulations have problems such as severe gastrointestinal side effects, poor patient compliance, and poor pharmacokinetics when used to treat excessive daytime sleepiness and cataplexy.
Method used
The teloridine formulation, which includes an alkaline reagent and an enteric coating, optimizes pharmacokinetics through the alkaline reagent and reduces gastric side effects by utilizing the enteric coating, thereby improving patient compliance.
Benefits of technology
It achieves faster time to peak drug absorption (Tmax), larger area under the curve (AUC), and higher bioavailability, while reducing gastric side effects and improving patient compliance.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122374013A_ABST
Abstract
The present application relates generally to dosage forms (e.g., oral dosage forms) and pharmaceutical compositions comprising a pharmaceutically active agent comprising telotristat or a pharmaceutically acceptable salt, solvate, or hydrate thereof; a basic agent; a delayed release coating; and optionally one or more pharmaceutically acceptable excipients; and to methods of using the dosage forms and pharmaceutical compositions, and methods of making the dosage forms and pharmaceutical compositions.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20040028737A1
Method for producing coated pharmaceuticals and food supplements with concentration gradients in the coating thereof
US20050271778A1
Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
US7138413B1
Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
US7169928B2
Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications
US7910605B2